Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
|Articles|November 18, 2013
Mini-quiz: Schizophrenia and Cannabis Use Disorder
Listen
0:00 / 0:00
Key Takeaways
- Comorbid cannabis use disorder affects about one-quarter of patients diagnosed with schizophrenia.
- Cannabis can trigger an acute psychotic presentation, particularly in vulnerable individuals.
What percentage of patients with schizophrenia have a comorbid cannabis use disorder? Take the quiz and learn more.
Advertisement
What percentage of patients with schizophrenia have a comorbid cannabis use disorder?
For the answer,
Answer: D. 25% of patients with schizophrenia have a comorbid cannabis use disorder.
While research suggests that cannabis use can induce an acute psychotic state, there is controversy about whether it may precipitate psychotic disorders, such as schizophrenia. However, a history of cannabis misuse is more common in patients who are schizophrenic than in the general population.
For more on this topic,
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Don't miss out on these CME articles! Test your knowledge here.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
2
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
The Psychiatric Pipeline in Review: Quarter 3, 2026
5